Ohio State Navbar

Sign In

Jeffery J. Auletta, MD

Jeffery J. Auletta, M.D.
Director, Host Defense Program
Hematology/Oncology/BMT & Infectious Diseases
Nationwide Children’s Hospital
Associate Professor, Department of Pediatrics
The Ohio State University College of Medicine
Phone: (614) 722-6883
Email: jeffery.auletta@nationwidechildrens.org

In addition to their regenerative capacity, mesenchymal stromal cells (MSCs) and multipotent adult-progenitor cells (MAPCs) are currently being investigated as cellular therapies for aberrant auto- and allo-immune diseases. An emerging role for these cells also suggests their involvement in antimicrobial host defense. My interests include defining the mechanisms underlying the immunomodulatory effects of MSCs and MAPCs in allogeneic stem cell transplant and infection. Such mechanistic investigation into the immunobiology of these cells will also serve to enhance their regenerative capacity and broaden their use in other clinical applications.

Research Interests

  • Cellular therapies for aberrant or absent immune response
  • Immune reconstitution following stem cell transplantation
  • Immunomodulatory effects of regenerative stromal cell therapies (mesenchymal stromal cells, MSCs, and multipotent adult progenitor cells, MAPCs)
  • Infections in immunocompromised patients
  • Innate immunity (Toll-like receptors, dendritic cells)
  • Microbiome-mediated immunomodulation

Selected Publications

Petrosuite A, Auletta JJ, Lazarus HM. Achieving graft-versus-tumor effect in brain tumor patients: from autologous progenitor cell transplant to active immunotherapy. Immunotherapy. 2012 Nov;4(11):1139-51.

Auletta JJ, Bartholomew AM, Maziarz RT, Deans RJ, Miller RH, Lazarus HM, Cohen JA. The potential of mesenchymal stromal cells as a novel cellular therapy for multiple sclerosis. Immunotherapy. 2012 May;4(5):529-47.

Auletta JJ, Deans RJ, Bartholomew AM. Emerging roles of multipotent, bone marrow-derived stromal cells in host defense. Blood. 2012 Feb 23;119(8):1801-9.

Auletta JJ, Zale EA, Welter JF, Solchaga LA. Fibroblast growth factor-2 enhances expansion of human bone marrow-derived mesenchymal stromal cells without diminishing their immunosuppressive potential. Stem Cells Int. 2011 Mar 3;2011:235176.

Auletta JJ, Cooke KR, Solchaga LA, Deans RJ, van’t Hof W. Regenerative stromal cell therapy in allogeneic hematopoietic stem cell transplantation: current impact and future directions. Biol Blood Marrow Transplant. 2010 Jul;16(7):891-906.

Auletta JJ, Cooke KR. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease. Curr Opin Pediatr. 2009 Feb;21(1):30-8.

Auletta JJ, Lazarus HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant. 2005 May;35(9):835-57.

Auletta JJ, Devecchio JL, Ferrara JL, Heinzel FP. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2004 Dec;10(12):834-47.